Samer Al'Hadidi, MD, discusses monitoring strategies for patients with relapsed/refractory multiple myeloma who are receiving lenalidomide.
Relapsed/Refractory Multiple Myeloma Algorithm
An expert on the treatment of multiple myeloma discusses the role of CAR T-cell therapy in relapsed/refractory disease.
In a discussion with the Oncology Brothers on the treatment of patients with relapsed/refractory multiple myeloma, Samer Al'Hadidi, MD, discusses adverse effects associated with CAR T-cell therapy and bispecific antibodies.
Rohit Gosain, MD, and Rahul Gosain, MD, are joined by Samer Al'Hadidi, MD, to discuss treatment decision-making strategies for patients with relapsed/refractory multiple myeloma.
Samer Al'Hadidi, MD, offers advice to community oncologists who treat patients with relapsed/refractory multiple myeloma, and the Oncology Brothers recap the entire discussion.
Advertisement
Advertisement
Trending on CancerNetwork
1
Investigational Radioenhancer Shows Feasibility in Stage III NSCLC
2
Subcutaneous Isatuximab May Optimize Multiple Myeloma Treatment Protocols
3
Mechanistic and Translational Insights of CARv3-TEAM-E in Glioblastoma
4
104 KATSIS-1: Randomized Phase 3 Trial Evaluating KAT6 Inhibitor PF-07248144 (prifetrastat) Plus Fulvestrant in HR+HER2− Advanced/Metastatic Breast Cancer After Progression on CDK4/6 Inhibitor-Based Therapy
5